查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1677035

抗菌胜肽市场按来源、结构、作用机制和应用划分 - 2025 年至 2030 年全球预测

Antimicrobial Peptides Market by Source, Structure, Mechanism of Action, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

抗菌肽市场预计在 2024 年价值 10.5 亿美元，2025 年价值 11.5 亿美元，到 2030 年预计将达到 19 亿美元，复合年增长率为 10.44%。

主要市场统计数据
基准年 2024 年 10.5亿美元
预计 2025 年 11.5亿美元
预测年份 2030 19亿美元
复合年增长率（%） 10.44％

抗菌肽已成为一类强大的生物分子，能够解决现代医学中一些最迫切的挑战。随着抗生素抗药性的增加和致病威胁的不断演变，抗菌肽不仅因其固有的抗菌特性而且因其在各个行业中的广泛应用而受到广泛关注。全球科学界和市场相关人员已表现出显着的转变，开始探索天然和合成来源，从而推动了技术创新和治疗突破。目前的天然分离化合物和合成类似物的混合格局是由严格的研究、强有力的临床研究和策略性投资所支撑的。

本介绍对抗菌肽市场进行了深入检验，并强调了抗菌肽在转变治疗模式中将发挥的关键作用。它邀请决策者和专家深入研究市场动态、市场区隔趋势和市场发展的分析广度。随着新的临床资料和技术进步的融合，适应性策略和前瞻性领导将决定这些有前景的分子转化为有效治疗方案的速度。

改变抗菌肽市场

近年来，在技术突破、法律规范不断发展和消费者需求动态的推动下，抗菌肽市场经历了变革性变化。胜肽合成和分子工程的进步使研究人员能够提高这些分子的效力、稳定性和特异性。特别是，创新的製造技术和数位模拟工具使得胜肽序列的快速原型设计和最佳化成为可能。这些突破不仅加快了从发现到上市的时间，而且拓宽了其应用范围。

随着对对照临床试验和全面安全评估的重视程度不断提高，情况正在改变。世界各地的监管机构正在逐步简化核准流程，同时确保满足严格的安全标准。此外，对个人化医疗和标靶治疗的重新关注正在鼓励产业相关人员投资下一代研究平台。这种持续的演变为生物技术公司、学术机构和临床医生之间的策略合作奠定了基础。多学科专业知识的结合对于克服与胜肽药物相关的传统挑战、实现更快的市场渗透和提高治疗效果具有关键作用。

推动市场策略的关键细分洞察

详细的細項分析显示，抗菌肽市场由一系列细微的分类定义，每种分类都有助于全面了解该行业。细分来说，首先从胜肽的来源开始，分成天然胜肽和合成胜肽。来自动物、微生物和植物来源的天然胜肽代表了具有内在生物活性的多样化化合物库，而合成胜肽可以进行精确的修改以提高功效和安全性。

另一个重要的细分是基于这些化合物的结构组成。 α-螺旋肽因其有效靶向细胞膜的能力而受到认可，其β-片层结构在生物环境中提供稳定性和弹性，其环状结构提供独特的动态特性，对于客製化治疗应用具有吸引力。除了结构分类之外，重点的是作用机制。有些胜肽透过细胞内标靶化发挥作用并直接影响细胞过程，而有些胜肽则利用膜孔形成来破坏致病细胞的完整性。

最后，从应用的角度来看，市场正在向农业、化妆品和食品工业等领域扩展，其中製药业占有显着地位。抗菌药物可对抗抗药性感染，抗癌胜肽为标靶治疗提供了新方法，抗真菌和抗病毒胜肽可应对新出现的微生物威胁，免疫调节剂和创伤治疗配方为患者康復提供重要支持。这种多层次的细分框架使相关人员能够利用详细的见解，协调产品开发策略并有效分配资源。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 抗生素抗药性不断上升推动对替代抗菌肽的需求
      • 肽合成的进展提高了抗菌肽的稳定性和功效
      • 加大研发投入，推动抗菌胜肽新型应用开发
    • 限制因素
      • 高生产成本和扩大规模的挑战限制了抗菌肽的广泛应用
    • 机会
      • 新兴市场医疗基础设施不断扩大推动抗菌肽需求
      • 消费者对个人护理和农业领域永续抗菌产品的需求不断增加
    • 任务
      • 全球监管障碍使抗菌肽的市场进入和商业化变得复杂
  • 市场区隔分析
    • 来源：天然抗菌肽对抗感染疾病和支持防御机制的重要性
    • 用途：抗菌肽在治疗感染疾病、癌症和促进创伤治疗的药用应用
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 抗菌肽市场（依来源）

  • 自然的
    • 动物
    • 微生物
    • 植物
  • 合成

第七章 抗菌肽市场结构

  • 阿尔法螺旋
  • Beta 表
  • 环形

8. 抗菌肽市场（依作用机制划分）

  • 细胞内标靶化
  • 孔隙形成

第九章 抗菌肽市场（依应用）

  • 农业
  • 化妆品
  • 食物
  • 药品
    • 抗菌
    • 抗癌药物
    • 抗真菌
    • 抗病毒药物
    • 免疫调节
    • 伤口癒合

第 10 章美洲抗生素胜肽市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第 11 章亚太地区抗菌胜肽市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲抗菌肽市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amferia AB
  • AnaSpec Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Celdara Medical, LLC
  • Eli Lilly and Company
  • EnBiotix Inc.
  • Hello Bio
  • Ingenza Limited
  • Johnson & Johnson Services, Inc.
  • Magainin Pharmaceuticals, Inc.
  • Matrubials Inc.
  • MaxWell Biosciences
  • Meddenovo Drug Design
  • Melinta Therapeutics
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Nuritas Ltd.
  • Peptilogics
  • Pfizer Inc.
  • Toagosei Co Ltd
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-0E33FCE5BD4D

The Antimicrobial Peptides Market was valued at USD 1.05 billion in 2024 and is projected to grow to USD 1.15 billion in 2025, with a CAGR of 10.44%, reaching USD 1.90 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.05 billion
Estimated Year [2025] USD 1.15 billion
Forecast Year [2030] USD 1.90 billion
CAGR (%) 10.44%

Antimicrobial peptides have emerged as a powerful class of biomolecules with the capacity to address some of the most pressing challenges in modern medicine. In the wake of escalating antibiotic resistance and evolving pathogenic threats, these peptides are garnering significant attention not only for their intrinsic antimicrobial properties but also for their versatile applications in various industries. The global scientific community and market stakeholders have witnessed a notable shift towards exploring both natural and synthetic sources, spurring innovation and therapeutic breakthroughs. With a blend of naturally isolated compounds and engineered analogs, the current landscape is underpinned by rigorous research, robust clinical studies, and strategic investments.

This introduction sets the stage for a detailed examination of the antimicrobial peptides market, emphasizing the crucial role these agents play in revolutionizing treatment paradigms. It invites decision-makers and experts to delve into the analytical expanse of market dynamics, segmentation trends, and regional developments. As emerging clinical data and technology advances converge, the stage is set for a transformative era in which adaptive strategies and forward-thinking leadership will determine the pace at which these promising molecules are translated into effective therapeutic solutions.

Transformative Shifts in the Antimicrobial Peptides Market Landscape

Recent years have witnessed transformative shifts in the antimicrobial peptides market, driven by technological breakthroughs, evolving regulatory frameworks, and dynamic consumer demands. Advancements in peptide synthesis and molecular engineering have enabled researchers to enhance the potency, stability, and specificity of these molecules. In particular, innovative manufacturing techniques and digital simulation tools now facilitate rapid prototyping and optimization of peptide sequences. Such breakthroughs are not only accelerating the timeline from discovery to market but are also broadening the spectrum of applications.

The landscape has shifted as well due to an increased emphasis on controlled clinical trials and comprehensive safety evaluations. Global regulatory bodies are progressively streamlining approval processes while ensuring that robust safety standards are met. Moreover, a renewed focus on personalized medicine and targeted therapies has galvanized industry players to invest in next-generation research platforms. This ongoing evolution is setting a foundation where strategic collaborations between biotech firms, academic institutions, and clinical practitioners are becoming pivotal. The convergence of interdisciplinary expertise is proving instrumental in overcoming traditional challenges associated with peptide-based drugs, thus enabling faster market penetration and heightened therapeutic efficacy.

Key Segmentation Insights Driving Market Strategies

In-depth segmentation analysis reveals that the market for antimicrobial peptides is defined by a series of nuanced classifications, each contributing to a holistic understanding of the industry. The segmentation begins with the source of these peptides, which is divided into natural and synthetic. Natural peptides, derived from animal, microbial, and plant origins, offer a diverse repository of compounds with intrinsic biological activity, while synthetic peptides allow for precise modifications designed to enhance efficacy and safety.

Another crucial segmentation is based on the structural makeup of these compounds. Alpha-helical peptides are recognized for their ability to target cell membranes efficiently, beta-sheet conformations offer stability and resilience in biological environments, and loop structures provide unique dynamic properties that are attractive for bespoke therapeutic applications. Beyond structural classifications, a critical dimension is the mechanism of action. Certain peptides exert their effects through intracellular targeting, influencing cellular processes directly, whereas others employ membrane pore formation to disrupt the integrity of pathogenic cells.

Lastly, when viewed through the prism of application, the market extends its reach across sectors such as agriculture, cosmetics, and food industries, with a significantly robust presence in pharmaceuticals. Within the pharmaceutical subset, the focus is multifaceted: antibacterial agents combat resistant infections, anticancer peptides offer novel approaches for targeted therapy, antifungal and antiviral peptides address emergent microbial threats, while immunomodulatory agents and wound healing formulations contribute to critical support in patient recovery. This layered segmentation framework enables stakeholders to harness detailed insights, tailor their product development strategies, and allocate resources efficiently, thereby driving market growth and innovation.

Based on Source, market is studied across Natural and Synthetic. The Natural is further studied across Animal, Microbial, and Plant.

Based on Structure, market is studied across Alpha-helical, Beta-sheet, and Loop.

Based on Mechanism of Action, market is studied across Intracellular Targeting and Membrane Pore Formation.

Based on Application, market is studied across Agriculture, Cosmetics, Food, and Pharmaceuticals. The Pharmaceuticals is further studied across Antibacterial, Anticancer, Antifungal, Antiviral, Immunomodulation, and Wound healing.

Global Regional Perspectives on Antimicrobial Peptides

A critical examination of the antimicrobial peptides market from a regional perspective reveals distinct trends that vary by geography. The Americas continue to play a dominant role, with research institutions and pharmaceutical companies fuelling progress through cutting-edge clinical studies and a supportive regulatory climate. This region's robust infrastructure and investment in biotechnology underpin dynamic advancements, ensuring that innovative therapies reach the market faster.

In Europe, Middle East & Africa, the emphasis is on blending deep-rooted scientific expertise with emergent innovation hubs. The region benefits from a mosaic of research excellence, diverse clinical trials, and strategic public-private partnerships. European markets, in particular, showcase strong collaborations in the field of healthcare, while the Middle East and Africa are rapidly emerging as competitive landscapes due to enhanced regulatory support and investment in advanced research facilities.

The Asia-Pacific is distinguished by its accelerated industrial progress and sustained growth in the biotechnology sector. Rapid economic development, coupled with significant government investments in healthcare and life sciences, has made this region a fertile ground for the adoption of antimicrobial peptides. Here, high population densities and evolving healthcare needs are driving both public and private sector initiatives to harness the therapeutic potential of these biomolecules. Together, these regional insights offer a comprehensive view of how local market dynamics are aligning with global trends, providing a strategic guide for investors and innovators alike.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Market Leaders and Key Industry Innovators

The competitive landscape of the antimicrobial peptides market is characterized by the presence of several key companies, each contributing uniquely with extensive research expertise and technological innovations. Globally recognized pharmaceutical giants such as AbbVie Inc., Alexion Pharmaceuticals, Inc., and AstraZeneca plc have been instrumental in driving the evolution of this field. Their robust R&D initiatives and expansive clinical pipelines have significantly advanced the development of both natural and synthetic peptide therapies.

Simultaneously, companies like Amferia AB, AnaSpec Inc., Bayer AG, and Boehringer Ingelheim International GmbH have established themselves as leaders by focusing on niche segments and leveraging cutting-edge technology to enhance the performance attributes of peptide-based formulations. Established industry players, including Eli Lilly and Company, Johnson & Johnson Services, Inc., and Novartis AG, reinforce the market with their strategic investments in long-term research programs and comprehensive clinical trials.

Emerging innovators such as EnBiotix Inc. and Hello Bio are redefining the market by integrating advanced biotechnological platforms with targeted therapeutic strategies. In addition, entities like Ingenza Limited and Magainin Pharmaceuticals, Inc. have introduced novel methodologies in drug design and customization, catering to unmet medical needs. Fresh market entrants such as Meddenovo Drug Design, Melinta Therapeutics, Merck KGaA, Novo Nordisk A/S, and Nuritas Ltd. have elevated industry dynamics through strategic collaborations and innovative product applications. Other influential companies including Peptilogics, Pfizer Inc., Toagosei Co Ltd, and Vertex Pharmaceuticals Incorporated have expanded market reach by adopting diverse distribution strategies and robust marketing frameworks. This collective array of corporate expertise underlines a competitive yet collaborative environment where innovation and strategic insight continue to propel the antimicrobial peptides market forward.

The report delves into recent significant developments in the Antimicrobial Peptides Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceuticals, Inc., Amferia AB, AnaSpec Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Celdara Medical, LLC, Eli Lilly and Company, EnBiotix Inc., Hello Bio, Ingenza Limited, Johnson & Johnson Services, Inc., Magainin Pharmaceuticals, Inc., Matrubials Inc., MaxWell Biosciences, Meddenovo Drug Design, Melinta Therapeutics, Merck KGaA, Novartis AG, Novo Nordisk A/S, Nuritas Ltd., Peptilogics, Pfizer Inc., Toagosei Co Ltd, and Vertex Pharmaceuticals Incorporated. Strategic Recommendations for Capitalizing on Market Opportunities

Industry leaders should prioritize robust research and development initiatives while embracing strategic partnerships to maintain a competitive edge in the antimicrobial peptides market. It is essential to invest in technology platforms that enhance peptide synthesis and structural optimization, as these innovations can substantially improve therapeutic profiles and market applicability.

Leaders are encouraged to implement targeted clinical trial designs and forge alliances with academic institutions and biotech firms to accelerate product development. A keen focus on integrating digital analytics with market intelligence will allow companies to monitor evolving trends, adapt to regulatory changes, and respond swiftly to emerging consumer needs. Furthermore, aligning investment strategies with clear segmentation insights-spanning source, structure, mechanism of action, and application-ensures that new products are developed with precision and market relevance.

Adopting a dual approach that leverages both global market trends and localized regional dynamics will enable organizations to optimize product distribution and capitalize on demographic-specific opportunities. Comprehensive market understanding and agile operational strategies will empower industry leaders to drive sustainable growth, innovate continuously, and secure their positions in an increasingly competitive landscape.

Final Thoughts on the Future of the Antimicrobial Peptides Market

In conclusion, the antimicrobial peptides market is positioned for significant growth driven by groundbreaking scientific research and innovative therapeutic applications. The complex interplay between natural and synthetic sources, along with an intricate understanding of structural and mechanistic nuances, offers diverse opportunities across multiple sectors. A careful segmentation of the market into source, structure, mechanism, and application not only enhances clarity but also aligns strategic planning with evolving clinical needs.

The integration of regional trends further enriches the market narrative, showcasing dynamic progress in the Americas, Europe, Middle East & Africa, and Asia-Pacific. With a broad spectrum of industry giants and innovative disruptors pushing the boundaries of peptide research, the path forward is marked by strategic collaboration and sustained investment. Collectively, these factors underscore a transformative era in which antimicrobial peptides are set to redefine modern therapeutics and contribute to improved patient outcomes worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising antibiotic resistance boosting demand for antimicrobial peptides as alternatives
      • 5.1.1.2. Advancements in peptide synthesis enhancing stability and efficacy of antimicrobial peptides
      • 5.1.1.3. Increased R&D investments driving the development of novel antimicrobial peptide applications
    • 5.1.2. Restraints
      • 5.1.2.1. High production costs and scaling challenges limiting widespread adoption of antimicrobial peptides
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing healthcare infrastructure in emerging markets creating demand for antimicrobial peptides
      • 5.1.3.2. Increasing consumer demand for sustainable antimicrobial products in personal care and agriculture
    • 5.1.4. Challenges
      • 5.1.4.1. Global regulatory hurdles complicating antimicrobial peptide market entry and commercialization
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Source: Significance of natural antimicrobial peptides in combating infections and supporting defense mechanisms
    • 5.2.2. Application: Pharmaceutical applications of antimicrobial peptides in treating infections, cancer, and promoting wound healing
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antimicrobial Peptides Market, by Source

  • 6.1. Introduction
  • 6.2. Natural
    • 6.2.1. Animal
    • 6.2.2. Microbial
    • 6.2.3. Plant
  • 6.3. Synthetic

7. Antimicrobial Peptides Market, by Structure

  • 7.1. Introduction
  • 7.2. Alpha-helical
  • 7.3. Beta-sheet
  • 7.4. Loop

8. Antimicrobial Peptides Market, by Mechanism of Action

  • 8.1. Introduction
  • 8.2. Intracellular Targeting
  • 8.3. Membrane Pore Formation

9. Antimicrobial Peptides Market, by Application

  • 9.1. Introduction
  • 9.2. Agriculture
  • 9.3. Cosmetics
  • 9.4. Food
  • 9.5. Pharmaceuticals
    • 9.5.1. Antibacterial
    • 9.5.2. Anticancer
    • 9.5.3. Antifungal
    • 9.5.4. Antiviral
    • 9.5.5. Immunomodulation
    • 9.5.6. Wound healing

10. Americas Antimicrobial Peptides Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antimicrobial Peptides Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antimicrobial Peptides Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Beiersdorf and Macro Biologics unite to innovate biodegradable antimicrobial peptides for skin care and healthcare solutions
    • 13.3.2. Amferia's EUR 1.2 million investment increases antimicrobial peptide technology, commercial expansion, and resistance fight
    • 13.3.3. Revolutionary dmSLAY method enhances antimicrobial peptides by improving safety and selectivity
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Amferia AB
  • 4. AnaSpec Inc.
  • 5. AstraZeneca plc
  • 6. Bayer AG
  • 7. Boehringer Ingelheim International GmbH
  • 8. Celdara Medical, LLC
  • 9. Eli Lilly and Company
  • 10. EnBiotix Inc.
  • 11. Hello Bio
  • 12. Ingenza Limited
  • 13. Johnson & Johnson Services, Inc.
  • 14. Magainin Pharmaceuticals, Inc.
  • 15. Matrubials Inc.
  • 16. MaxWell Biosciences
  • 17. Meddenovo Drug Design
  • 18. Melinta Therapeutics
  • 19. Merck KGaA
  • 20. Novartis AG
  • 21. Novo Nordisk A/S
  • 22. Nuritas Ltd.
  • 23. Peptilogics
  • 24. Pfizer Inc.
  • 25. Toagosei Co Ltd
  • 26. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. ANTIMICROBIAL PEPTIDES MARKET MULTI-CURRENCY
  • FIGURE 2. ANTIMICROBIAL PEPTIDES MARKET MULTI-LANGUAGE
  • FIGURE 3. ANTIMICROBIAL PEPTIDES MARKET RESEARCH PROCESS
  • FIGURE 4. ANTIMICROBIAL PEPTIDES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ANTIMICROBIAL PEPTIDES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. ANTIMICROBIAL PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIMICROBIAL PEPTIDES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIMICROBIAL PEPTIDES MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY ANIMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY ALPHA-HELICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY BETA-SHEET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY LOOP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY INTRACELLULAR TARGETING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MEMBRANE PORE FORMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COSMETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY FOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY ANTIBACTERIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY ANTICANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY ANTIFUNGAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY ANTIVIRAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY IMMUNOMODULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 283. ANTIMICROBIAL PEPTIDES MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 284. ANTIMICROBIAL PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2024